Long-term effects of Aldara 5% cream and Solaraze 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA).

Trial Profile

Long-term effects of Aldara 5% cream and Solaraze 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA).

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2013

At a glance

  • Drugs Imiquimod (Primary) ; Diclofenac
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms LEIDA; LEIDA (IMIQ vs. DIC)
  • Sponsors Meda Pharma GmbH & Co KG
  • Most Recent Events

    • 07 Jul 2012 Primary endpoint changed from Disease-recurrence to Disease-recurrence-rate as reported by European Clinical Trials Database record.
    • 07 Jul 2012 Almirall S.A. added as associations as reported in the European Clinical Trials Database record.
    • 05 Jan 2011 Planned end date changed from Apr 2012 to Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top